China to use drug bulk-buy program to close price gap

China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.

Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine

German biotech company Morphosys' tafasitamab, the group's most advanced drug which is currently being tested, has sales potential of significantly more than $1 billion a year, its finance chief said in remarks to a magazine.

Drinking-related liver disease and deaths on the rise in U.S.

(Reuters Health) - Americans today are expected to live shorter lives than just a few years ago, in contrast with trends seen in other developed nations, and rising deaths from alcohol-related liver disease may be partly to blame, researchers say.